The coronavirus disease 2019 (COVID-19) emerged around December 2019 and have become a global epidemic disease currently. Specific antibodies against SAS-COV-2 could be detected in COVID-19 patients’ serum or plasma, but the clinical values of these antibodies as well as the effects of clinical drugs on humoral responses have not been fully demonstrated. In this study, 112 plasma samples were collected from 36 patients diagnosed with laboratory-confirmed COVID-19 in the Fifth Affiliated Hospital of Sun Yat-sen University. The IgG and IgM antibodies against receptor binding domain (RBD) and spike protein subunit 1 (S1) of SAS-COV-2 were detected by ELISA. We found that COVID-19 patients generated specific antibodies against SARS-CoV-2 after infection, and the levels of anti-RBD IgG within 2 to 3 weeks from onset were negatively associated with the time of positive-to-negative conversion of SARS-CoV-2 nucleic acid. Patients with severe symptoms had higher levels of anti-RBD IgG in 2 to 3 weeks from onset. The use of chloroquine did not significantly influence the patients’ antibody titer but reduced C-reaction protein (CRP) level. Using anti-viral drugs (lopinavir/ritonavir or arbidol) reduced antibody titer and peripheral lymphocyte count. While glucocorticoid therapy developed lower levels of peripheral lymphocyte count and higher levels of CRP, lactate dehydrogenase (LDH), α-Hydroxybutyrate dehydrogenase(α-HBDH), total bilirubin (TBIL), direct bilirubin (DBIL). From these results, we suggested that the anti-RBD IgG may provide an early protection of host humoral responses against SAS-COV-2 infection within 2 to 3 weeks from onset, and clinical treatment with different drugs displayed distinct roles in humoral and inflammatory responses.
【저자키워드】 COVID-19, SARS-CoV-2, Chloroquine, antibody, Humoral response, 【초록키워드】 coronavirus disease, Coronavirus disease 2019, Arbidol, therapy, Chloroquine, Lopinavir/ritonavir, Inflammatory responses, Lopinavir, Ritonavir, Infection, LDH, CRP, drug, lactate dehydrogenase, glucocorticoid, ELISA, Spike protein, Receptor binding domain, Protein, lymphocyte, serum, Epidemic, IgM antibodies, RBD, Patient, Antibody titer, plasma, humoral responses, university, disease, anti-viral drug, COVID-19 patients, specific antibodies, Lactate, Anti-viral drugs, Protein subunit, Clinical treatment, Bilirubin, COVID-19 patient, humoral, Anti-RBD IgG, IgG and IgM, epidemic disease, Affiliated Hospital, hydroxybutyrate dehydrogenase, Sun Yat-sen, direct bilirubin, total bilirubin, subunit, Laboratory-confirmed COVID-19, plasma samples, severe symptoms, SARS-CoV-2 nucleic acid, Specific, laboratory-confirmed, while, Host, peripheral lymphocyte, α-Hydroxybutyrate dehydrogenase, Effect, plasma sample, collected, significantly, diagnosed, specific antibody, reduced, demonstrated, suggested, severe symptom, 【제목키워드】 drug, clinical, response, Effect,